熱門資訊> 正文
波士顿科学公司获得FDA批准Farmense心脏标测产品
2024-10-19 04:58
- Boston Scientific (NYSE:BSX) said it has received FDA approval for its Farawave NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation and Faraview software.
- The products are used to provide visualization during pulsed field ablation, or PFA, procedures with the company's Farapulse PFA system.
- The technologies are compatible with Boston Scientific’s existing cardiac mapping technology and its Opal HDx Mapping System. according to a statement.
- Boston Scientific received FDA clearance for its Farapulse PFA System for the treatment of atrial fibrillation in January.
More on Boston Scientific
- Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
- Boston Scientific Corporation (BSX) Wells Fargo 2024 Healthcare Conference (Transcript)
- Boston Scientific Corporation (BSX) Q2 2024 Earnings Call Transcript
- Boston Scientific cut to Hold at Needham on growth concerns
- Boston Scientific closes Silk Road Medical acquisition
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
